ALX Oncology Holdings Statistics
Total Valuation
ALXO has a market cap or net worth of $82.47 million. The enterprise value is $23.63 million.
Important Dates
The next estimated earnings date is Monday, November 10, 2025, after market close.
| Earnings Date | Nov 10, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
ALXO has 53.55 million shares outstanding. The number of shares has increased by 11.80% in one year.
| Current Share Class | 53.55M |
| Shares Outstanding | 53.55M |
| Shares Change (YoY) | +11.80% |
| Shares Change (QoQ) | +0.16% |
| Owned by Insiders (%) | 2.80% |
| Owned by Institutions (%) | 29.07% |
| Float | 28.32M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.41 |
| P/TBV Ratio | 1.35 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.52, with a Debt / Equity ratio of 0.25.
| Current Ratio | 4.52 |
| Quick Ratio | 4.24 |
| Debt / Equity | 0.25 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -70.35 |
Financial Efficiency
Return on equity (ROE) is -104.21% and return on invested capital (ROIC) is -57.54%.
| Return on Equity (ROE) | -104.21% |
| Return on Assets (ROA) | -47.78% |
| Return on Invested Capital (ROIC) | -57.54% |
| Return on Capital Employed (ROCE) | -154.92% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.46M |
| Employee Count | 80 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +4.76% in the last 52 weeks. The beta is 1.22, so ALXO's price volatility has been higher than the market average.
| Beta (5Y) | 1.22 |
| 52-Week Price Change | +4.76% |
| 50-Day Moving Average | 1.44 |
| 200-Day Moving Average | 0.92 |
| Relative Strength Index (RSI) | 46.99 |
| Average Volume (20 Days) | 532,648 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -118.47M |
| Pretax Income | -116.57M |
| Net Income | -116.57M |
| EBITDA | -117.63M |
| EBIT | -118.47M |
| Earnings Per Share (EPS) | -$2.17 |
Full Income Statement Balance Sheet
The company has $79.31 million in cash and $16.18 million in debt, giving a net cash position of $63.13 million or $1.18 per share.
| Cash & Cash Equivalents | 79.31M |
| Total Debt | 16.18M |
| Net Cash | 63.13M |
| Net Cash Per Share | $1.18 |
| Equity (Book Value) | 64.42M |
| Book Value Per Share | 1.20 |
| Working Capital | 66.41M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$105.49 million and capital expenditures -$316,000, giving a free cash flow of -$105.81 million.
| Operating Cash Flow | -105.49M |
| Capital Expenditures | -316,000 |
| Free Cash Flow | -105.81M |
| FCF Per Share | -$1.98 |
Full Cash Flow Statement Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
ALXO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -11.80% |
| Shareholder Yield | -11.80% |
| Earnings Yield | -134.37% |
| FCF Yield | -121.96% |
Analyst Forecast
The average price target for ALXO is $3.30, which is 114.29% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $3.30 |
| Price Target Difference | 114.29% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Forecasts Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 3 |